Exchange: OTC·Updated 03:41 PM EDT
News
all
press releases
REGN Soars 21.9% in a Month: Buy, Sell or Hold the Stock?
Regeneron's Eylea HD and Dupixent strength are fueling growth, while oncology gains and pipeline progress support its outlook.
Zacks
More News
CYTK Q2 Earnings Top Estimates, Myqorzo Uptake Strong
CYTK tops Q2 revenue estimates as Myqorzo gains traction, but higher launch costs and the absence of milestone payments weigh on results.
Zacks
BAYRY Beats on Q2 Earnings, Crop Science Business Boosts Growth
Bayer tops Q2 estimates as Crop Science and fast-growing drugs offset pressure from patent-expired brands, while reaffirming its 2026 outlook.
Zacks
Regeneron Q2 Earnings Beat, Sales Up on Dupixent & Eylea HD Strength
REGN's Q2 earnings and revenues beat estimates as robust Eylea HD demand and higher Dupixent profits offset declining Eylea sales.
Zacks
Is CTVA Stock Worth Buying After a Powerful Rally and Earnings Beat?
Corteva's earnings beat, rising estimates and innovation pipeline support momentum, but premium valuation and separation costs raise execution risk.
Zacks
Why Corteva's Seed and Crop Protection Engines Matter to Investors
CTVA's Seed pricing, Crop Protection volumes and cost savings support growth ahead of its planned fourth-quarter 2026 separation.
Zacks
How Corteva's Innovation Pipeline Could Shape Its Next Growth Cycle
CTVA's $2 billion crop-protection pipeline, royalty gains and 2026 split could sharpen its technology-led growth story.
Zacks
Top Research Reports for SAP, UBS & Cadence
SAP reaffirmed 2026 guidance as UBS advances Credit Suisse integration and Cadence boosts AI momentum. See the latest research highlights.
Zacks
Novartis to Expand Oncology Pipeline With Myricx Bio Acquisition
NVS plans to acquire Myricx Bio for up to $1.5 billion, adding novel ADC technology to expand its oncology pipeline and tumor targets.
Zacks
NVS Gains EC Approval for SMA Therapy Itvisma in Broad Population
Novartis wins EC approval for Itvisma, the first gene replacement therapy for a broad SMA population, expanding treatment options from newborns to adults.
Zacks

Advertisement|Remove ads.